Athenex Inc. (ATNXQ)

[Leotrader211]

Companies are exploring the clinical benefits of fusing new chemical entities in existing drugs on treatment of bile duct cancer. The key players in global bile duct cancer treatment market are also seeking regulatory approval of combination therapies for treatment of Cholangiocarcinoma. The study has recorded such developments while profiling the market’s leading participants, which include Pfizer, Inc., F. Hoffman-La Roche AG, Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, Novartis AG, Sanofi, Fresenius Kabi AG, Mylan N.V., Kyowa Hakko Kirin Co Ltd., Intercept Pharmaceuticals, Inc., Accord Healthcare Inc., Delcath Systems Inc.,Celgene Corporation, and Johnson & Johnson. 

http://www.satprnews.com/2018/02/05/global-bile-duct-cancer-treatment-market-will-reach-a-valuation-of-us-144-2-mn-between-2017-and-2025/ ;